Investment

Regenerative gene therapies

Investment

The innovative method of male contraceptive

New biofuel from used coffee beans

Fulcrum offers medicine of the future

New medicines to deliver a new future for patients and their families by transforming gene regulation in disease were developed by Fulcrum Therapeutics. This company is spinoff of Harvard University.  The sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. The Fulcrum product engine is based on the breakthrough biology of gene regulation. It will bring to bear medicines for devastating diseases across multiple therapeutic areas by modulating – or balancing – the expression of the genes known to drive disease.

by
22 days ago

The breakthrough technology to induce new human hair growth

Hair-Regeneration Method was developed by researchers at Columbia University Medical Center. Scientists have devised a hair restoration method that can generate new human hair growth, rather than simply redistribute hair from one part of the scalp to another. The approach could significantly expand the use of hair transplantation to women with hair loss, who tend to have insufficient donor hair, as well as to men in early stages of baldness. It could make hair transplantation available to individuals with a limited number of follicles, including those with female-pattern hair loss, scarring alopecia, and hair loss due to burns.

22 days ago

The new class of medicines for rare diseases

The Cambridge-based company uses messenger RNA to produce human proteins inside patient cells, which offers an innovative way to deliver drugs to a patient. This company is called Moderna Therapeutics. They are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. It could transform not only how certain diseases are treated but also how medicines are discovered, developed and manufactured – at a breadth, scale and speed not common in the biopharma industry. Since founding, the company has built the industry’s leading mRNA technology platform, the infrastructure to accelerate drug discovery and speed early development, a rapidly expanding pipeline, and an unparalleled team. Their development pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and they have multiple clinical trials already underway with other development candidates progressing toward the clinic. 

by
22 days ago

Empowering the fight against cancer

Transforming drug discovery for Neurodegenerative Diseases

Macrobian Biotech provides new treatments for neurodegenerative diseases

Gene therapy for treating rheumatic diseases

Arthrogen is developing local gene therapy for inflammatory diseases, using viral-mediated gene transfer. The first target indication is in the field of rheumatic diseases. The company is spinoff of Amsterdam UMC (AUMC). Gene therapy could allow life transforming single treatments of chronic diseases with a good safety profile. The Arthrogen therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans. The recombinant viruses are engineered to express therapeutic proteins or genes that can knock-down proteins that are involved in the pathogenesis of rheumatic diseases. Arthrogen BV was founded in 2005 as a joint venture between the Dubai Bone & Joint Center (DBAJ) in the United Arab Emirates and the Academic Medical Center (AMC) in Amsterdam, the Netherlands. Arthrogen has managed to raise almost €15M so far to support its pipeline for inflammatory disease.

by
22 days ago

The new approach for people suffering from severe liver diseases

The new technology for restoring liver function was developed by Ambys Medicines. The company is working to fundamentally transform the lives of people suffering from severe liver diseases by creating breakthrough therapies capable of restoring liver function, preventing the progression of liver disease, and treating the devastating complications of liver failure. This company is pioneering multiple novel technologies - including liver cell therapy, liver reprogramming gene therapies, and liver-targeted drug therapies — to meet the urgent need for treatments that reverse disease progression across multiple liver diseases that are untreatable or poorly treated today. Mortality rates due to chronic liver disease and cirrhosis of the liver are on an alarming upward trajectory. New interventions to manage the morbidity and mortality of end-stage liver disease are needed urgently.

by
22 days ago

In-silico enzymes detecting platform

EnzBond is an innovative British start-up developed within Oxford University by the research team Dr. Alina Rakhimova, Dr. Robert Simion, Lachlan Mackinnon and Prof. Steve Davies. EnzBond has changed the current understanding of the enzyme evolution process and made a breakthrough in biotechnology of enzyme treatment. The technology allows accelerated optimisation of biocatalysts used for the production of small molecules by predicting enzyme activity with high accuracy and at speeds faster than alternative methods. EnzBond's technology is only mechanism dependent, meaning that it can be applied to any enzyme notwithstanding sequence, structure or catalytic characteristics. With penetrate enzyme design technology it became possible to improve enzymes used in the pipeline, discover and optimise enzymes that could be applied to the processes and create a brand new custom enzyme for drug production and treatment purposes of such diseases, as for example, Gaucher disease, Fabry disease, MPS I, MPS II (Hunter syndrome), MPS VI, Pompe disease etc.

by
22 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 VENTURE CLIENT PLATFORM